BioSeeker launches new report "The Global Structure of Prostate Cancer R&D"

In Europe and the US there are close to 20 million people that live with cancer today, a figure that is increasing. 6.2 million people worldwide died of cancer in 1998. The American Cancer Society estimates that approximately 1.2 million new cancer cases were diagnosed in the year 2000 in the US. Overall annual costs associated with cancer currently amount to $107 billion in the United States alone. The worldwide anti-cancer market was valued at more than $15 billion in 1998 and is projected to nearly double by 2003. Approximately 30% of all collaborative deals are signed in the field of cancer.

According to the American Cancer Society, after skin cancer, prostate cancer is the most common type of cancer found in American men and is the second leading cause of cancer deaths in men, exceeded only by lung cancer. In 2003, there will be an estimated 221 000 new cases of prostate cancer in the United States, and about 29 000 men will die of the disease.

The Global Structure of Prostate Cancer R&D is one of the most comprehensive and up to date information sources currently available in the prostate cancer R&D arena. Information about new innovative cancer therapies such as antisense, monoclonal antibodies, gene therapy, antigen- or cellular-based vaccines, liposomal hormones and apoptotic drugs are analyzed in more than 100 extensive tables and graphs. This report wil give you easy-to-read tables with projects classified into well-defined structures based on type of therapy given, effect and mecanism. The graphs provide all the relations of these factors as well as the general and specific trends in the current prostate cancer pipeline.

Included in this 250+ page report:

Information on more that 160 companies active in prostate cancer R&D

Information on more that 300 industry related prostate cancer projects

Data from 170 clinical trials

Information on more than 130 preclinical projects

92 graphs illustrating the most important relations between types of therapy, effects and mecanisms

Advanced analysis of general and specific trends in the pipeline

Some of the companies analysed in this report include Abbott Laboratories, AEterna Laboratories, Alfacell, AlphaVax, ALZA, Aronex Pharmaceuticals, AstraZeneca, Aventis, AVI BioPharma, Baxter, Biogen, BioVex, Bristol-Myers Squibb Co, Celera Genomics, Celgene, Cell Therapeutics, CellGenix, Cephalon, Corautus, Corixa, Coulter Pharmaceutical, Cytel, Dendreon, Eli Lilly & Co, F Hoffmann-La Roche, Fujisawa Pharmaceuticals, Genentech, GlaxoSmithKline, GTx, Hybridon, IDEC Pharma, ILEX Oncology, ImClone/BMS/Merck, Immunex, Immunomedics, ISIS Pharmaceuticals, Maxim Pharmaceuticals, Medarex, Millennium, ML Laboratories, Novogen, Oncology Sciences, Paladin Labs, Pfizer, Pharmacia, PSMA Development Company (PDC), Roche Holding, Seattle Genetics, Takeda Chemical Industries, Transgene, Wyeth Pharmaceuticals, Yamanouchi Pharmaceutical Co, YM Biosciences.

The Global Structure of Prostate Cancer R&D is an excellent source of information providing a solid presentation of exciting and rapidly evolving therapeutics and enabling companies to establish potential partners and competitors.

The report is also available in several different electronic file formats, to enable you with independent updating and structuring of the material.

This report will assist you in:

Tracking cutting edge companies, therapies and new technologies

Rapid identification of partners & competitors

Laying down a comprehensive framework for further analysis of the field

Producing presentations surrounding the development of prostate cancer therapeutics

Identifying emerging prostate cancer products & key areas of pharmaceutical R&D

Publication date: Sept. 18 2003

Price: $1950 (PDF), $2000 (Hardcopy)

Size: 254 pages

To click here!